Oncolytics Biotech Inc. · NASDAQ:ONCY

Oncolytics Biotech — Investor Presentation (December 2011)

13 slides from Oncolytics Biotech's investor presentation, December 2011

  1. Slide 1: Investor Presentation December 2011

    TSX:ONC NASDAQ:ONCY Investor Presentation December 2011 0 Forward Looking Statements Today’s presentation contains certain forward looking statements relating to the company’s financial results, results business prospects and the development and commercialization of REOLYSIN®, a therapeutic reovirus

  2. Slide 2: Oncolytics Overview / Selected Oncolytics Pipeline

    Oncolytics Overview REOLYSIN – A Broadly Active Novel Cancer Therapy ƒ Focused Clinical Program • Lead product is REOLYSIN® • Phase III REOLYSIN and paclitaxel/carboplatin in platinum-refractory h d and head d neckk cancer patients i (i (international i l study) d ) • Randomized Phase 2 REOLYSIN and

  3. Slide 3: REOLYSIN Overview and Mechanism of Action

    REOLYSIN Overview ƒ REOLYSIN is a proprietary isolate of the reovirus, a replication competent virus ƒ Reovirus is considered safe to humans ƒ REOLYSIN has been safely administered to patients via intravenous, intratumoural, and intrathecal injection ƒ Mechanism of Action: • In Ras-activated cancer

  4. Slide 4: REOLYSIN Selectivity / Market for Ras Pathway Mediated Cancers

    REOLYSIN Selectivity ƒ Slide shows positive (red staining) for reovirus in the cancer cells (black arrow), relative to the normal cells (red arrow) ƒ 9 out of 10 patients showed the same pattern, i.e. targeted delivery to metastatic tumour lesions of the liver. Two of the patients had complete tumou

  5. Slide 5: Pivotal (Phase III) Program for REOLYSIN

    Pivotal (Phase III) Program for REOLYSIN Study Overview ƒ Phase Ph III ttrial i l examining i i REOLYSIN in i combination bi ti with ith paclitaxel/carboplatin lit l/ b l ti iin ttaxane-naïve ï patients with platinum-refractory head and neck cancers ƒ Trial and statistical design reviewed by FDA und

  6. Slide 6: Interim Results Compared to Historical Controls

    Interim Results Compared to Historical Controls Second-Line Therapies In Platinum Refractory Head and Neck Patients Treatment Reference Response Rate Median TTP or PFS Median Survival (months) (months) Various Treatments or Léon et al., 2005 2.6% N/A 3.0 Best Supportive care Docetaxel Specenier et a

  7. Slide 7: Metastatic Nasopharyngeal Case Study / US Phase 2 Ovarian

    Phase II REOLYSIN/Paclitaxel/Carboplatin — Metastatic Nasopharyngeal Case Study P t t Pre-treatment t P t cycle Post l 3 Prior treatment Results ƒ Radiation – 2 cycles ƒ Target lesion – liver metastases ƒ Cisplatin, gemcitabine/carboplatin, ƒ Baseline – 59.4 mm carboplatin/5-FU – 6 cycles ƒ Post cyc

  8. Slide 8: Phase 2 Studies of REOLYSIN in Pancreatic Cancer

    Phase 2 Studies of REOLYSIN in Pancreatic Cancer US Phase 2 Program ƒ > 90% of pancreatic cancers have Kras mutations ƒ Single arm study examining use of REOLYSIN/gemzar combination in patients with advanced or metastatic pancreatic cancer with measurable disease who have not received any prior chem

  9. Slide 9: Phase 2 NSCLC and Kras/EGFR

    US Phase 2 SCCLC: REOLYSIN/Carbo/Taxol Combination Pt 0001 – Partial Response (PR) in Lung Pre-treatment Post 2 Cycles Post 4 Cycles Ri ht U Right Upper L Lung M Mass (8 (8.3 3 cm)) Ri ht U Right Upper L Lung M Mass (4 (4.1cm) 1 ) Ri ht U Right Upper L Lung M Mass (3 (3.6cm) 6 ) Right pleural met (2

  10. Slide 10: Colorectal Cancer and Kras

    US Phase 2 NSCLC: REOLYSIN/Carbo/Taxol Combination – Partial Response (PR) in Lung by CT (EGFR Mutation) Pre-treatment Post Cycle 2 ƒ FISH for EGFR (Red) and CEP7 (Green) ƒ Ex19 18bp in-frame deletion and T790M mutation 18 Colorectal Cancer and Kras ƒ Current standard of care for second-line patient

  11. Slide 11: Safety and Intellectual Property

    Safety ƒ >420 patients treated, >330 intravenously at doses up to 3x1010 TCID50 daily. ƒ No maximum tolerated dose (MTD) reached to date. ƒ Monotherapy toxicities have been generally mild (grade 1 or 2) and included chills, fever, headache, cough, myalgia, runny nose, sore throat and fatigue, and gr

  12. Slide 12: Manufacturing / Market & Capital Data

    Manufacturing ƒ Now produced at 100L under cGMP with final formulation ƒ Commercial manufacturing agreement with SAFC in place 22 Market & Capital Data E h Exchanges NASDAQ ONCY NASDAQ:ONCY TSX:ONC Shares Outstanding (Sept. 30, 2011) 71,239,918 Warrants Expiring Price Nov 8, 2012 $6.15 1,794,750 Nov

  13. Slide 13: Oncolytics Summary

    Oncolytics Summary REOLYSIN – A Broadly Active Novel Cancer Therapy ƒ Focused Clinical Program • Lead product is REOLYSIN® • Phase III REOLYSIN and paclitaxel/carboplatin in platinum-refractory h d and head d neckk cancer patients i (i (international i l study) d ) • Randomized Phase 2 REOLYSIN and

Oncolytics Biotech — Investor Presentation (December 2011) on 6ix